Anakinra versus treatment as usual in the treatment of acute gout
Acute gout is a common form of inflammatory arthropathy characterized by severe pain and reduced physical functioning. The current standard treatments, colchicine, corticosteroids or NSAIDs, are therefore designed to rapidly relieve the pain and inflammation in the affected joints. Although gout is one of the most well understood rheumatic diseases, currently available treatment options are frequently contra-indicated or poorly tolerated by gout patients, which frequently presents in the presence of significant multi-morbidity (hypertension and renal disease). Anakinra, a DNA recombinant interleukin-1 receptor antagonist, is a medicinal product currently registered for the treatment of rheumatoid arthritis. The clinical efficacy and safety of anakinra in acute gout have been investigated and reported in a handful of case series or small open-label studies. The goal of this research project is to determine whether anakinra could be a safe, more applicable and possibly more effective agent to treat gouty arthritis.